KR101838379B1 - Composition for increasing salivary secretion, or prevention, improvement or treatment of xerostomia of disorder of salivation comprising curcuma xanthorrhiza extract or xanthorrhizol - Google Patents

Abstract

Nag of the present invention or the sol Java turmeric (Curcuma relates to a composition comprising a xanthorrhiza) extract as an active ingredient, the composition promotes gene and the activity of the protein associated with the saliva secreted by the salivary gland cells, and by increasing the concentration of intracellular Ca ^{2 +} increase the electrolyte secretion of liquid It is possible to prevent, treat, or ameliorate oral dryness or saliva secretion abnormality through enhancement of saliva secretion, and can be used safely without adverse effect as a natural product, so that it can be effectively used for the production of medicines, quasi-drugs or foods.

Description

FIELD OF THE INVENTION The present invention relates to a composition for enhancing saliva secretion comprising an extract of Javanese Calcium Chloride or an active ingredient of Zanthoxyl Sulfate or a composition for preventing, ameliorating or treating the dry mouth syndrome of Xanthorrhiza EXTRACT OR XANTHORRHIZOL}

The present invention relates to a process for the preparation of xanthorrhizol or Curcuma xanthorrhiza ) extract or a composition for preventing, ameliorating or treating the above-mentioned salivary gland secretion or the like.

Saliva is the secretion secreted from the salivary gland into the oral cavity. In normal people, the average daily saliva is 1 to 1.5 liters. Approximately 99.5% of saliva is water and the remaining 0.5% is composed of electrolyte, mucus, glycoprotein, enzyme, and antimicrobial substance. Saliva lubricates the oral mucosa, protects the oral tissues, and engages in digestion, taste, and remineralization of teeth. In particular, many proteins present in saliva have a profound effect on oral microbiota due to antibacterial, antiviral and antifungal effects (Journal of Dentistry, 33: 223-233, 2005).

The secretion mechanism of saliva can be divided into protein secretion and secretion of liquid and electrolyte. In the case of protein secretion, the sympathetic norepinephrine (norepinephrine) binds to the β-adrenergic receptor located in the cell membrane at the bottom of the secretory endothelial cells to form heterotrimeric G- G-protein) and adenylyl cyclase are activated. When protein kinase A is activated by the formation of cyclic adenosine monophosphate, secretory granules in the cell membrane secrete the protein into the lumen by extracellular flux. On the other hand, secretion of liquid and electrolytes is mainly caused by the binding of acetylcholine, a parasympathetic neurotransmitter, to muscarinic receptors. When an agonist binds to a muscarinic receptor, heterotrimeric G-protein and phospholipase C are activated in turn, ultimately leading to inositol triphosphate , IP3) is promoted. IP₃ emits Ca ^{2 +,} which is stored in the cells, and by the density of the increased Ca ^{2 +} Cl present in the side lumen ^- a K ⁺ channel present in the side passageway with the bottom open, Na ⁺ / K ⁺ / ^2Cl-co- The co-transporter is activated. In addition, aquaporin 5 (AQP5) protein in follicles migrates to the lining membrane. The increased Cl ^- in the lumen side equilibrates along Na ⁺ , which moves through the closed synapse to the lumen, resulting in an osmotic gradient. The osmotic gradient moves water from the cell to the lumen through closed junction with AQP5 ( Annual Review of Physiology , 67: 445-469, 2005).

On the other hand, aquaporin is a water channel protein and is found in cornea, kidney, liver and skin. Aquaporins are rich in subfamilies from AQP0 to AQP12, and AQP5 is a major biomarker in saliva secretion. In particular, AQP5 knockout mice have been shown to reduce salivary secretion by more than 60% ( The Journal of Biological Chemistry , 274: 20071-20074, 1999).

Xerostomia is the most common clinical symptom associated with salivary glands. If the amount of saliva secreted during non - stimulation is less than 0.1 ml per minute, it is diagnosed as dry mouth. The cause of dry mouth syndrome is mainly adverse drug reactions such as antidepressant, antidiabetic, and antiallergic drugs. Oral dryness due to natural aging is caused by a decrease in the parenchymal tissue of the salivary gland, a substitution of adipose tissue, or a decrease in the volume of the acini. When the amount of saliva in the oral cavity is reduced, it is possible that the oral cavity, acid candidiasis, dysgeusia, dysphagia, oral dysesthesia, intraoral halitosis, ( The Journal of the American Dental Association , 138: S15-S20, 2007).

The most commonly used drugs for the treatment of oral dryness include parasympathomimetic pilocarpine, cevimeline, and bethanechol. However, these therapies have the disadvantage of causing side effects such as sweating, vomiting, vasodilation, diarrhea, and bronchospasm. Therefore, it is very important to prevent and treat dry mouth based on natural products with characteristics of low side effects and high safety.

Java turmeric is a kind of Zingiberaceae, Curcuma xanthorrhiza Roxb. It is used as a spice in the tropical regions of Southeast Asia and has been widely used as a traditional medicine due to its strong antioxidant and anti-inflammatory action. The Java turmeric is an antioxidant ( The Journal of Microbiology , 46: 228-232, 2008; Asian Pacific Journal of Tropical Biomedicine , 2: S637-S640, 2012), Evidence-based Complementary and Alternative Medicine (Article 2012: ), Anticancer ( Phytotherapy Research , 22: 695-698, 2008), gastrointestinal protection ( BioMed Research International , Article 2014: 416409, 2014), liver protection ( Journal of Medicinal Plants Research , 4: 2512-2517, 2010) Have been reported to have physiological activity.

The xanthorrhizol isolated from turmeric are Java antibacterial (Fitoterapia, 71: 321-323, 2000 ; Planta Medica, 66: 196-197, 2000), antifungal (Phytotherapy Research, 21: 434-438, 2007), anti-inflammatory (Journal of Environmental Pathology, Toxicology and Oncology, 21: 141-148, 2002), cancer (Biochemical and Biophysical Research Communications, 326 : 210-217, 2005), anti-aging (Phytotherapy Research, 23: 1299-1302, 2009), nerve ( Journal of Neuroscience Research , 82: 831-838, 2005).

However, prior to the present invention, there has been no detailed report on the prevention, improvement, or therapeutic effect of the salvage secretion abnormality or oral dryness of Javanese Turmeric extract or Zanthoxylate.

The present invention relates to a method for preventing or treating oral dryness or saliva secretion by promoting the activity of genes and proteins associated with salivary secretion in salivary gland cells and increasing the concentration of intracellular Ca ^{2 +} Which can be safely applied to human body as a natural product, and / or Java curcuma ( Curcuma xanthorrhiza extract of the present invention.

In order to achieve the above object, the present invention Java turmeric (Curcuma xanthorrhiza ) extract or a fraction thereof as an active ingredient.

Specifically, the present invention relates to a process for the preparation of curcuma xanthorrhiza ) extract or a fraction thereof as an active ingredient for the prevention or amelioration of salivary gland secretion enhancement or oral dryness or saliva secretion.

The invention also Java turmeric (Curcuma xanthorrhiza extract or a fraction thereof as an active ingredient for preventing or treating oral dryness or salivary gland dysfunction.

The invention also Java turmeric (Curcuma xanthorrhiza extract or fractions thereof as an active ingredient, or a quasi-drug composition and quasi-drug for the prevention or improvement of oral dryness or saliva secretion.

In another aspect, the present invention provides a composition comprising xanthorrhizol or a salt thereof as an active ingredient.

Specifically, the present invention provides a food composition for enhancing saliva secretion comprising xanthorrhizol or a salt thereof as an active ingredient, or for preventing or improving oral dryness or saliva secretion or the like.

The present invention also provides a pharmaceutical composition for preventing or treating dry mouth or salivary gland dysfunction, which comprises xanthorrhizol or a salt thereof as an active ingredient.

The present invention also provides a quasi-drug composition and quasi-drug for preventing or ameliorating saliva secretion enhancement comprising xanthorrhizol or a salt thereof as an active ingredient, or oral dry or saliva secretion.

Nag of the present invention or the sol Java turmeric (Curcuma xanthorrhiza) extract promotes gene and the activity of the protein associated with the saliva secreted by the salivary gland cells, cell by increasing the intracellular Ca concentration of ^{2 +} preventing dry mouth or saliva secretion through the enhancement of the electrolytic release of the liquid, treating or ameliorating And can be safely used as a natural product without side effects, and thus can be effectively used for the production of medicines, quasi-drugs, foods, and the like.

FIG. 1 shows the results of measurement of mRNA expression of AQP5 in human salivary glands (HSG) following treatment with Java turmeric extract.
Figure 2 shows the results of imaging the expression of AQP5 protein in human salivary gland cells (HSG) following treatment with Java turmeric extract.
FIG. 3 is a graph showing intracellular Ca2 + measured by the treatment with Java turmeric extract in human salivary gland cells (HSG).
FIG. 4 shows the results of measurement of mRNA expression of AQP5 in human salivary gland cells (HSG) following treatment with Janssol sol.
FIG. 5 shows the results of imaging the expression of AQP5 protein in human salivary gland cells (HSG) following treatment with Janssol sol.
Figure 6 is a graph measuring the concentration of intracellular Ca ^{2 +} in accordance with xanthorrhizol treatment in a human salivary gland cells (HSG).

The inventors of the present invention have searched and studied natural materials which can safely be applied with saliva enhancing effect for treating or ameliorating oral dryness and saliva secretion abnormality due to inferior function of salivary glands or atrophy, Curcuma xanthorrhiza ) extract or a fraction thereof has an effect of preventing or ameliorating oral dryness or saliva secretion, and completed the present invention.

Hereinafter, the present invention will be described in more detail.

The present invention relates to a process for the production of curcuma xanthorrhiza extract or fractions thereof as an active ingredient, or a composition for prevention, treatment or improvement of oral dryness or saliva secretion.

The present invention also relates to a composition for preventing, treating or improving salivary gland secretion enhancement or oral dryness or salivary gland secretion comprising zanthoxyl or a salt thereof as an active ingredient.

The 'Java turmeric' is a ginger plant native to Southeast Asia, and its scientific name is Curcuma xanthorrhiza . It is used as a spice in tropical regions of Southeast Asia and is known to have antioxidant activity.

The preparation of the extract of the present invention can be used in all parts of the above-described Java vulcanized plant, and the plant means that it contains all the processed products such as the dry. In the preparation of the extract of the present invention, there is no restriction on the site, but it may be the root of Curcuma xanthorrhiza .

In one embodiment of the invention, the Java turmeric (Kerr kyuma nagging characters) when treated with the extract, was the activity of the salivation-related gene and protein increase in salivary gland cells, to increase the in Ca ^{2 +} concentrations salivation It was experimentally confirmed that oral dryness or saliva secretion abnormality was improved by the enhancement.

The Java turmeric extract of the present invention may preferably contain xanthorrhizol. It was isolated and identified xanthorrhizol compound from Java turmeric extract In one embodiment of the invention, the Java turmeric extracts, as well as, the xanthorrhizol compound that increases the salivation-related gene and protein activity increase and Ca ^{2 +} concentrations in the salivary gland cells The results are shown in Fig.

The "xanthorrhizol (xanthorrhizol)" is a Java turmeric (Curcuma xanthorrhiza ), which is known to have an antimicrobial activity.

The above-mentioned nasolizol is a 2-methyl-5 - [(2r) -6-methylhept-5-en-2-yl] phenol -yl] phenol), preferably a compound represented by the following formula (1).

[Chemical Formula 1]

The composition of the present invention may contain a salt of the above-mentioned nansol sol as an active ingredient. The salt may be a pharmaceutically acceptable salt.

In addition, the salt may be prepared according to a conventional method for modifying and preparing the salt of the compound for producing the food or medicament of the present invention.

In one embodiment of the present invention, the Curcuma xanthorrhiza ) extracts. As a result, it was confirmed that zanthoxylate has an effect of increasing salivary secretion related gene and protein activity and Ca ^{2 +} concentration in salivary gland cells. Thus, the janssor sol of the present invention may be one extracted from Curcuma xanthorrhiza .

In the present invention, an 'extract' is a substance obtained by dissolving a substance in a solvent and separating the active ingredient or a characteristic component. In the present invention, specifically, an extract obtained by extracting the plant with an extracting solvent and an extract prepared by extracting the extract, To < / RTI > Therefore, the Curcuma xanthorrhiza extract of the present invention includes all the fractions obtained by extracting the extract of Curcuma xanthorrhiza by adding a solvent to Java turmeric and a fraction obtained by adding fraction solvent thereto.

Specifically, the extract may be an ethanol extract, a methanol extract, a hot water extract, a hexane extract, an ethyl acetate extract or an ultrahigh pressure extract using rhizome of a curcuma.

The extraction solvent may be at least one selected from the group consisting of water, an organic solvent, a subcritical fluid and a supercritical fluid. The organic solvent may be a polar solvent, a nonpolar solvent, a polar and nonpolar mixed solvent or water. Specific examples of the solvent include alcohols having 1 to 6 carbon atoms, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, hexane ), Cyclohexane, petroleum ether, and water.

In one embodiment of the present invention, the Curcuma adding ethanol to a xanthorrhiza) preparing the extract, and the Java turmeric ethanol increases salivary gland cells, salivary related gene and protein activity in the extract and intracellular Ca ^{2 +} bar hayeotneun determine the concentration increase effect, preferably ethanol as the extraction solvent to be used .

The plant extract may be one prepared by a conventional method for producing a plant extract. More specifically, the method may be carried out by adding an extraction solvent to the plant from which the impurities have been removed and performing an extraction process. The extraction process may be a cold extraction method, a warm extraction method, a pressure extraction method, or an ultrasonic pulverization extraction method. For example, a Curcuma xanthorrhiza plant may be obtained by extraction under an ultra-high pressure condition of 100 MPa or more.

The fraction solvent may be water, butanol, ethyl acetate, chloroform, hexane or a mixture thereof. The fraction may be an extract prepared by the above extraction method, specifically, a fraction obtained by further fractionating the crude extract. The fraction solvent may be a solvent selected from the group consisting of ethyl acetate, ether, chloroform, benzene, hexane, methylene chloride, and mixed solvents thereof. More specifically, the fractionation step may be performed by adding a fraction solvent to the crude extract to obtain a fractionated fraction. The fractions may also be fractionated by adding a fraction solvent to obtain fractions.

In one embodiment of the invention, the fraction is obtained from Curcuma < RTI ID = 0.0 > xanthorrhiza ) ethanol extract with a mixed solvent of hexane and ethyl acetate.

The mixed solvent may include hexane and ethyl acetate in a volume ratio of 5-15: 1, preferably in a volume ratio of 7-13: 1, more preferably in a volume ratio of 8-11: 1 Lt; / RTI > When the above-mentioned mixed solvent is used, the content of pesticide sols in the fraction can be further increased, and it has an excellent effect on enhancing saliva secretion, or preventing, treating or improving more than oral secretion or saliva secretion.

In addition, the fractions were obtained from Curcuma xanthorrhiza ) ethanol extract with a mixed solvent of hexane and ethyl acetate and fractionating the first fraction with methanol as a developing solvent.

After the extraction or fractionation, the extract or fraction may be subjected to a vacuum filtration process or may be further concentrated and / or lyophilized to concentrate or remove the solvent. The extracts obtained can be stored in a deep freezer until use.

The fractions can be prepared using specific techniques such as solvent fractionation, silica gel chromatography, prep-HPLC, and the like to produce specific fractions in which the active substance is concentrated.

 In this specification, "saliva" is also referred to as saliva, which means a colorless viscous digestive juice secreted from the salivary glands of the mouth (salivary gland). In general, the amount of saliva secreted for 24 hours in a normal person is about 1000 to 1500 ml. Generally, when not stimulated by autonomic nerve, it produces 0.001 ~ 0.2ml per minute, and when stimulated, the flow rate increases to 0.18 ~ 1.7ml per minute. The average secretion per minute is about 1mL. About 99% of it is water, and it contains various minerals.

In this specification, the term 'disorder of salivation' means a symptom in which the secretion of saliva is less than or greater than normal. In the present invention, it is preferable that the saliva secretion is less than normal. In this context, 'salivary gland dysfunction' means a disease in which the abnormal salivary glands manifest disease levels. The saliva secretion abnormality can eventually develop into dry mouth syndrome. The composition comprising the extract of the present invention or the nansol sol may be a composition for enhancing saliva secretion in that saliva secretion is enhanced to improve the saliva secretion less than normal.

In the present specification, "oral dry" or "dry mouth" refers to a symptom in which saliva is reduced or the mouth is dry due to various other causes. Specifically, if the amount of saliva secreted for 24 hours is less than 1000 to 1500 ml, the user may feel that the mouth is dry and dry, or that the oral cavity is dry due to evaporation of moisture in the mouth while breathing through the mouth.

The above-mentioned 'abnormal saliva secretion' or 'dry mouth' refers to the side effects and side effects of administration of Sjören's syndrome, chronic inflammatory disease, radiation therapy or salivary insults caused by it, severe diarrhea, systemic water loss, diabetes, nutrient deficiency, Diabetes, an antidepressant, or a side effect of an antiallergic drug.

In one embodiment of the present invention, treatment of the salivary gland cells with Janssorzol or the extract of the present invention can increase saliva secretion by increasing AQP5 gene and protein expression and intracellular Ca ²⁺ concentration in salivary gland saliva secretion Respectively. Accordingly, the composition of the present invention can prevent, treat, or ameliorate oral dryness or salivation due to salivary gland malfunction, dysfunction of the salivary glands, atrophy, or other causes of salivary gland secretion due to activation of saliva secretion in salivary gland cells can do.

As used herein, " prevention " refers to any action that inhibits or delays the onset of a disease or condition. In the present invention, it means activation of salivary secretion action of salivary glands to delay or delay the onset of symptom of salivary gland malfunction, hypofunction of salivary glands, atrophy or other causes of decreased salivation.

In the present invention, 'improvement' refers to all actions that alleviate or alleviate a disease or pathological condition. In the present invention, the salivary gland secretion action is activated to cause a salivary gland malfunction, a malfunctioning of the salivary gland, This means that the saliva secretion is reduced and the symptoms of mouth dryness and mouth dryness are improved.

In the present invention, the term " treatment " means any action that delays, stops or reverses the progress of disease or pathology. In the present invention, the salivary gland secretion action is activated in the present invention to cause salivary gland malfunction, Means to stop, alleviate, relieve, relieve, or reverse the symptoms of dry mouth and mouth dryness caused by decreased saliva secretion by cause.

In one embodiment of the present invention Java turmeric (Curcuma xanthorrhiza extract or zanthoxyl saliva to increase the saliva secretion action of the salivary gland to treat salivary glands or dry mouth. Therefore, in this aspect, the composition of the present invention may be a pharmaceutical composition for enhancing saliva secretion, or for preventing or treating dry mouth or saliva secretion or the like.

The pharmaceutical composition includes not only humans but also animals other than humans. The pharmaceutical composition for animals other than humans includes animal medicines, medicinal intermediates and quasi-drugs.

The composition of the present invention may further contain one or more active ingredients having the same or similar functions in addition to the above-described effective ingredients for enhancing saliva secretion, or for preventing or treating oral dryness or salivation. For example, it may further include a known oral dry symptom therapeutic agent which is effective for enhancing saliva secretion, or preventing or treating oral dryness or saliva secretion abnormality. Including the additional components can further enhance the preventive or therapeutic effect of the composition of the present invention. When the above components are added, stability in combination use, easiness in formulation, and stability of effective ingredients can be considered. The additional component may be included in an amount of 0.0001 wt% or more to 10 wt% or less based on the total weight of the composition. For example, from 0.0001 wt% to 1 wt%, from 0.0001 wt% to 0.1 wt%, from 0.0001 wt% to 0.001 wt%, from 0.001 wt% to 10 wt%, from 0.001 wt% 0.001 wt% or more to 0.1 wt% or less, 0.01 wt% or more to 10 wt% or less, or 0.01 wt% or more to 1 wt% or less. Such a content range may be adjusted according to safety, requirements for ease of formulation of the Curcuma xanthorrhiza extract of the present invention, or the preparation of the Nansorizole compound.

The pharmaceutical compositions of the present invention may include pharmaceutically acceptable salts of the < RTI ID = 0.0 > The term " pharmaceutically acceptable " as used herein refers to those which are physiologically acceptable and do not normally cause an allergic reaction or a similar reaction when administered to humans, and the salts include pharmaceutically acceptable free acids acid is preferred.

The pharmaceutically acceptable salt may be an acid addition salt formed using an organic acid or an inorganic acid. The organic acid may be, for example, formic acid, acetic acid, propionic acid, lactic acid, butyric acid, isobutyric acid, trifluoroacetic acid, malic acid, But are not limited to, malonic acid, fumaric acid, succinic acid, succinic monoamide, glutamic acid, tartaric acid, oxalic acid, citric acid, glycolic acid, glucuronic acid, ascorbic acid, benzoic acid, phthalic acid, salicylic acid, anthranilic acid, dichloroacetic acid, aminooxyacetic acid, Toluenesulfonic acid or methanesulfonic acid. The inorganic acid includes, for example, hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, nitric acid, carbonic acid or boric acid. The acid addition salt may preferably be in the form of a hydrochloride or an acetate, more preferably in the form of a hydrochloride.

The above-mentioned acid addition salts may be prepared by a) directly mixing the azaSol sol and the acid, b) dissolving and mixing one of them in a solvent or a water solvent, or c) placing the yazosol sol in a solvent or an acid in an anhydrous solvent And mixing them.

Separately, additionally saltable forms include, but are not limited to, the salts of gabapentin, gabapentin, pregabalin, nicotinate, adipate, hemimarate, cysteine, acetylcysteine, methionine, arginine, lysine, Aspartate and the like.

In addition, the pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier.

The pharmaceutically acceptable carrier may further include, for example, a carrier for oral administration or a carrier for parenteral administration. Carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. In addition, the carrier for parenteral administration may contain water, a suitable oil, saline, aqueous glucose and glycol, and the like. In addition, stabilizers and preservatives may be further included. Suitable stabilizers include antioxidants such as sodium hydrogen sulfite, sodium sulfite or ascorbic acid. Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol. Other pharmaceutically acceptable carriers can be found in Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, Pa., 1995).

The pharmaceutical composition of the present invention can be administered to mammals including humans by any method. For example, it can be administered orally or parenterally, and parenteral administration methods include, but are not limited to, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, , Intranasal, enteral, topical, sublingual or rectal administration.

The pharmaceutical composition of the present invention may be formulated into oral or parenteral dosage forms according to the route of administration as described above. When formulated, one or more buffers (e. G., Saline or PBS), carbohydrates (e. G., Glucose, mannose, sucrose or dextran), antioxidants, bacteriostats, chelating agents Diluents or excipients such as suspending agents, diluents or glutathione), fillers, extenders, binders, adjuvants (e.g., aluminum hydroxides), suspending agents, thickening agents, disintegrating or surfactants, diluents or excipients.

Solid preparations for oral administration include tablets, pills, powders, granules, solutions, gels, syrups, slurries, suspensions or capsules, etc. These solid preparations can be prepared by incorporating into the pharmaceutical composition of the present invention at least one excipient, , Starch (including corn starch, wheat starch, rice starch and potato starch), calcium carbonate, sucrose, lactose, dextrose, sorbitol, mannitol, xylitol, erythritol maltitol, , Methyl cellulose, sodium carboxymethyl cellulose and hydroxypropylmethyl-cellulose or gelatin. For example, tablets or tablets may be obtained by combining the active ingredient with a solid excipient, then milling it, adding suitable auxiliaries, and processing the mixture into granules.

In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions or syrups. In addition to water or liquid paraffin, which is a simple diluent commonly used, various excipients such as wetting agents, sweeteners, fragrances or preservatives may be included .

In addition, crosslinked polyvinylpyrrolidone, agar, alginic acid, or sodium alginate may optionally be added as a disintegrant, and may further include an anticoagulant, a lubricant, a wetting agent, a flavoring agent, an emulsifying agent and an antiseptic agent .

For parenteral administration, the pharmaceutical compositions of the present invention may be formulated in accordance with methods known in the art in the form of injectable, transdermal and nasal inhalers, together with suitable non-oral carriers. In the case of such injections, they must be sterilized and protected against contamination of microorganisms such as bacteria and fungi. Examples of suitable carriers for injectables include, but are not limited to, solvents or dispersion media containing water, ethanol, polyols (e.g., glycerol, propylene glycol and liquid polyethylene glycol, etc.), mixtures thereof and / or vegetable oils . More preferably, suitable carriers include isotonic solutions such as Hanks' solution, Ringer's solution, phosphate buffered saline (PBS) containing triethanolamine, or sterile water for injection, 10% ethanol, 40% propylene glycol and 5% dextrose Etc. may be used. In order to protect the injection from microbial contamination, various antibacterial and antifungal agents such as parabens, chlorobutanol, phenol, sorbic acid, thimerosal and the like may be further included. In addition, the injections may in most cases additionally include isotonic agents, such as sugars or sodium chloride.

Examples of transdermal dosage forms include ointments, creams, lotions, gels, solutions for external use, pastes, liniments, and air lozenges. By " transdermal administration " as used herein, it is meant that the pharmaceutical composition is locally administered to the skin, whereby an effective amount of the active ingredient contained in the pharmaceutical composition is delivered into the skin.

In the case of an inhalation dosage form, the compounds used according to the invention can be formulated into a pressurized pack or a pressurized pack using a suitable propellant, for example dichlorofluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gases. It can be conveniently delivered in the form of an aerosol spray from a nebulizer. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve that delivers a metered amount. For example, gelatin capsules and cartridges used in inhalers or insufflators may be formulated to contain the compound and a powder mixture of suitable powder base such as lactose or starch. Formulations for parenteral administration are described in Remington's Pharmaceutical Science, 15th Edition, 1975. Mack Publishing Company, Easton, Pennsylvania 18042, Chapter 87: Blaug, Seymour, commonly known in all pharmaceutical chemistries.

The pharmaceutical composition of the present invention can provide a desired saliva secretion enhancement when containing an effective amount of the active ingredient, or prevent, improve or treat the above-mentioned saliva secretion or dry mouth. As used herein, the term " effective amount " refers to an amount that exhibits a reaction higher than that of a negative control, and preferably refers to an amount sufficient to prevent, ameliorate, or treat salivation, or oral dryness or salivation. Nag the pharmaceutical composition of the present invention, the sol or Java turmeric (Curcuma xanthorrhiza ) extract may be contained in an amount of 0.01 to 99.99%, and the balance may be occupied by a pharmaceutically acceptable carrier. Nag included in the pharmaceutical compositions of the present invention, the sol or Java turmeric (Curcuma xanthorrhiza ) extract or fractions thereof will vary depending on the form in which the composition is produced.

The total effective amount of the pharmaceutical composition of the present invention may be administered to a patient in a single dose and may be administered by a fractionated treatment protocol administered over a prolonged period of time in multiple doses . The pharmaceutical composition of the present invention may vary in the content of the active ingredient depending on the degree of the disease. For example, Jansori sol or Java turc xanthorrhiza ) extract per day, preferably in an amount of 0.001 to 100 mg, more preferably 0.01 to 10 mg per kg of body weight per day. However, the dose of the above-mentioned extracts of Jansori sol or Curcuma xanthorrhiza is not limited to the administration route and the number of treatments of the pharmaceutical composition, but also various factors such as the patient's age, weight, health, sex, severity of disease, Since it is determined by the amount of the effective dose to the patient, if the person having ordinary knowledge in the art in view of this point the xanthorrhizol or Java turmeric (Curcuma xanthorrhiza ) extract may be used to determine an appropriate effective dose depending on the particular use for preventing, treating or ameliorating dry mouth or salivary gland dysfunction. The pharmaceutical composition according to the present invention is not particularly limited to the formulation, administration route and administration method as long as the effect of the present invention is exhibited.

The pharmaceutical compositions for preventing or treating saliva secretion enhancement or oral dryness or salivary secretion of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy or biological response modifiers .

Saliva secretion enhancer or a pharmaceutical for preventing or treating dry mouth or saliva secretion or more compositions of the invention can also xanthorrhizol or Java turmeric (Curcuma xanthorrhiza ) extract as an active ingredient. In this respect, the composition of the present invention may be a quasi-drug composition for preventing or ameliorating saliva secretion enhancement, or oral dry or saliva secretion, or a quasi-drug comprising the composition.

 The external agent may be applied directly to the skin or oral cavity. When the composition of the present invention is used as a external preparation, it may further contain at least one selected from the group consisting of fatty substances, organic solvents, solubilizers, thickening and gelling agents, softening agents, antioxidants, suspending agents, stabilizing agents, foaming agents, Such as an ionic emulsifier, a nonionic emulsifier, a filler, a chelating agent, a chelating agent, a preservative, a vitamin, a barrier agent, a humectant, a essential oil, a dye, a pigment, a hydrophilic activator, a lipophilic activator or a lipid vesicle And any other ingredients used in the skin sciences. In addition, the components can be introduced in amounts commonly used in the dermatology field.

When the composition of the present invention is provided as a external preparation, it may be a formulation such as, but not limited to, a liquid, an ointment, a patch, a gel, a cream or a spray. According to one embodiment of the present invention, the quasi-drug of the present invention may include an oral care product including toothpaste, a mouthwash and a mouse spray, an ointment, a mask, a poultice, a patch, and a percutaneous absorbent.

In one embodiment of the present invention, the salivary secretion action of the salivary gland is increased when treating Jansorizol or Java turmeric extract, and when the active ingredient is applied to the oral care product, salivary secretion action of the salivary gland is increased, Or symptoms of dry mouth due to abnormal salivary secretion and symptoms caused thereby. Therefore, the quasi-drug composition may be a composition for oral administration for preventing or improving saliva secretion enhancement, oral dryness, or saliva secretion.

When the composition of the present invention is used as a quasi-drug composition, it may be added as it is, or may be suitably used according to a conventional method together with other quasi-drug components. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (prevention, health or therapeutic treatment).

The contents of the pharmaceutical composition and the food composition of the present invention can be applied mutatis mutandis to the quasi-drug composition and quasi-drug of the present invention.

The composition of the present invention relates to a food composition for enhancing saliva secretion in another aspect, or for preventing or improving odor or saliva secretion.

The food composition may be a health functional food composition.

In addition, the food composition includes all foods intended for animals other than humans, in addition to foods intended for humans. Foods intended for animals other than humans include, for example, animal feeds, Animal feed additives, and animal supplements.

In one embodiment of the present invention, it was confirmed that when the extract of Jasmine or Java was treated, the dry saliva of the mouth could be improved by increasing the saliva secretion action of the salivary gland.

The food composition of the present invention includes all forms of functional foods, nutritional supplements, health foods, food additives and feeds, It is targeted for eating.

Food compositions of this type may be prepared in a variety of forms according to conventional methods known in the art. Common foods include but are not limited to beverages (including alcoholic beverages), fruits and processed foods (eg, canned fruits, jam, maamalade, etc.), fish, meat and processed foods (Eg butter, chewing), edible vegetable oil, margarine (such as corn oil, etc.), breads and noodles (eg udon, buckwheat noodles, ramen noodles, spaghetti, macaroni, etc.), juice, various drinks, cookies, , Vegetable protein, retort food, frozen food, various kinds of seasonings (for example, soybean paste, soy sauce, sauces, etc.) by adding the above-mentioned extracts of Janssoriz or Curcuma xanthorrhiza .

Further, nutritional supplements include, but are not limited to capsules, tablets, pills, etc. The nag sol or Java turmeric (Curcuma xanthorrhiza ) extract.

In addition, health functional foods include, but are not limited to, the above-mentioned Jazorizol or Curcuma xanthorrhiza ) extracts themselves can be prepared in the form of tea, juice and drink and liquefied, granulated, encapsulated and powdered for drinking (health drinks). In addition, the Java xanthorrhizol or turmeric (Curcuma xanthorrhiza ) extract may be used in the form of powder or concentrate for use as a food additive. In addition, the Java xanthorrhizol or turmeric (Curcuma xanthorrhiza extract and a known active ingredient known to be effective for preventing or ameliorating dry mouth syndrome or salivary gland dysfunction, in the form of a composition.

When the food composition of the present invention is used as a health beverage composition, the health beverage composition may contain various flavors or natural carbohydrates as additional components such as ordinary beverages. The above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose; Disaccharides such as maltose, sucrose; Polysaccharides such as dextrin, cyclodextrin; Xylitol, sorbitol, erythritol, and the like. Sweeteners include natural sweeteners such as tau Martin and stevia extract; Synthetic sweetening agents such as saccharin and aspartame, and the like can be used. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the composition of the present invention.

Jasmine or Java Curcuma xanthorrhiza extract of the present invention may be contained as an active ingredient of a food composition for preventing or ameliorating dry mouth or salivary gland dysfunction. The amount of the xanthorrhiza extract is particularly limited in an amount effective to prevent or improve saliva secretion enhancement or oral dryness or saliva secretion But it is preferably 0.0001 to 100% by weight based on the total weight of the total composition. Food compositions of the present invention xanthorrhizol or Java turmeric (Curcuma xanthorrhiza ) extract with other active ingredients known to be effective in preventing or inhibiting dry mouth or salivary gland dysfunction.

In addition to the above, the health food of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acid, protective colloid thickener, pH adjusting agent, Glycerin, an alcohol or a carbonating agent, and the like. In addition, the health food of the present invention may contain natural fruit juice, fruit juice drink, or pulp for the production of vegetable drinks. These components may be used independently or in combination. Although the ratio of such additives is not critical, it is generally selected in the range of 0.0001 to 0.1 part by weight per 100 parts by weight of the composition of the present invention.

Hereinafter, the present invention will be described in more detail by way of examples. It should be understood, however, that there is no intention to limit the invention to the specific forms disclosed, and it is to be understood that the invention is not limited to the disclosed embodiments, but, on the contrary, It is not. It is to be understood that the scope of the present invention includes all modifications, equivalents, and alternatives falling within the scope and spirit of the present invention.

Reference Example 1: Substance information of xanthorrhizol

Name: Xanthorrhizol; 2-methyl-5 - [(2R) -6-methylhept-5-en-2-yl] phenol

CAS No .: 30199-26-9

[ Example ]

[ Example  One] Java turbulence  Preparation of extract

Example  1-1. Java turbulence  Preparation of Rhizome Ethanol Extract

The dried rhizome of Java was pulverized with a mixer, and 100 g of the ground rhizosphere sample was added to 1 L of ethanol and extracted at room temperature for 48 hours. The extracted sample was filtered with filter paper of Whatman No. 2, and the filtered extract was concentrated with a vacuum rotary condenser to remove the solvent component, thereby obtaining an ethanol extract of Java Persimmon root.

Example  1-2. Java turbulence  near distance Heat number  Preparation of extract

The dried rhizome of Java was pulverized with a mixer, and 100 g of the ground rhizosphere sample was added to 1 L of water and extracted with stirring at 80 ° C for 4 hours. The extracted sample was filtered with filter paper No. 2 of Wattman, and the filtered extract was concentrated with a vacuum rotary condenser to remove the solvent component to obtain a hot water extract of Java Persimmon root.

Example  1-3. Java turbulence  near distance Hexane  Preparation of extract

The dried rhizome of Java was pulverized with a mixer, and 100 g of the ground rhizosphere sample was added to 1 L of nucleic acid and extracted with stirring at room temperature for 60 minutes. The extracted sample was filtered with Wattman No. 2 filter paper, and the filtered extract was concentrated with a vacuum rotary condenser to remove the solvent component to obtain a hexane extract of Macaca fascicularis.

Example  1-4. Java turbulence  Preparation of rhizome ethyl acetate extract

The dried rhizome of Java was pulverized with a mixer, and 100 g of the ground rhizosphere sample was added to 1 L of ethyl acetate and extracted with stirring at room temperature for 60 minutes. The extracted sample was filtered with filter paper No. 2 of Wattman, and the filtered extract was concentrated with a vacuum rotary condenser to remove the solvent component to obtain an extract of ethyl acetate as a solvent.

[ Example  2] Jansori sol  detach

(11.1 g) obtained in the above-described Example 1-1 was placed in a column packed with silica gel, and a solvent system in which hexane and ethyl acetate were mixed at a ratio of 10: 1 (v / v) was used Lt; / RTI > The fractions were divided into 6 fractions according to the sorting procedure, and the fractions were concentrated and dried. Fraction 5 (Fraction 5) out of the 6 fractions was purified using Rp-18 reverse phase column chromatography (Lichroprep Rp-18 25-40 um, Merck & Co., Kenilworth, New Jersey, USA) Lt; / RTI > The fractions were divided into three fractions according to the above sorting order and concentrated and dried. The fraction 3 (fraction 3-3) of the three fractions was concentrated to dryness to separate the pure active substance, jazorizole (0.52 g) represented by the following formula (1).

[Chemical Formula 1]

[ Test Example  One] Java turbulence  Effect of ethanol extract on saliva secretion enhancement

Test Example  1-1. RT- PCR  through Java turbulence  The efficacy of the extract to enhance the secretion of saliva

Human salivary gland cells (HSG) were cultured in a 6-well microtiter plate in Dulbecco's Modified Eagle's medium containing 10% fetal bovine serum (FBS, Hyclone, Logan, UT, USA) Medium, Hyclone) at 5 x 10 cells / well. After 24 hours, the culture medium in the wells was removed. To the DMEM (Hyclone) containing 10% of FBS (Hyclone), the ethanol extract of Java rootstock rhizome of Example 1-1 was added to 1 μg / ml and 10 μg / And the cells were treated for 20 minutes. RT-PCR was performed to determine the mRNA expression level of AQP5, a major protein expressed in saliva secretion. Total RNA was isolated from the cells using TRIzol reagent (Takara, Tokyo, Japan). The isolated total RNA was quantified using NanoDrop 1000 (Thermo Fisher Scientific, Waltham, Mass., USA). The quantified 16 ㎕ of RNA was amplified by PCR using a Reverse Transcriptase Premix (ELPIS-Biotech, Daejeon, Korea) and a PCR machine (Gene Amp PCR System 2700, Applied Biosystems, Waltham, Were synthesized as cDNA. (Bioneer, Daejeon, Korea) and HiPi PCR Premix (ELPIS-Biotech) for 30 sec at 95 ° C, 1 min at 53 ° C, 1 min at 72 ° C PCR was repeated 23 times.

AQP5:

Forward primer: 5'-AAGACCATGGAGCTGACCAC-3 '

Reverse primer: 5'-CCCTCTCTAACTGTGCAGCC-3 '

GAPDH:

Forward primer: 5'-CTCCTGTTCGACAGTCAGCC-3 '

Reverse primer: 5'-TCGCCCCACTTGATTTTGGA-3 '

As a result, as shown in Fig. 1, it was confirmed that the amount of AQP5 mRNA expression in human salivary gland cells was increased by the treatment with Java turmeric extract. This means that the Java turmeric extract of the present invention is excellent in enhancing the saliva secretion enhancing effect.

Test Example  1-2. AQP5  By comparing the expression levels of proteins Java turbulence  The efficacy of the extract to enhance the secretion of saliva

The coding sequence of human AQP5 was synthesized and cloned into the Kpn I and BamH I restriction sites of the pEGFP-C1 vector to construct a pEGFP-C1 vector with the AQP5 gene inserted (Bioneer, Daejeon , Korea). DMEM (Hyclone) medium containing 10% FBS (Hyclone) was added to a confocal dish (102350, SPL Life Sciences, Pocheon, Gyeonggi, Korea), and human salivary gland cells (HSG) Well, and cultured for 24 hours to attach the cells to the dish. 10 μl of a pEGFP vector inserted with a positive reagent (Invitrogen, Carlsbad, Calif., USA) and AQP5 gene sequence were mixed and incubated for 15 minutes. Lipofectamine (Invitrogen) After incubation at room temperature for 15 minutes, the cells were dropped on the cells attached to the dish. The cells were incubated at 37 ° C for 4 hours and then incubated overnight by changing to DMEM (Hyclone) medium containing FBS (Hyclone). The ethanol extract of Javanese Rhizoma of Example 1-1 was dissolved in a concentration of 10 / / ml for 20 minutes. Then, the AQP5 protein tagged with green fluorescent protein (GFP) was analyzed with a confocal microscope confocal microscope, LSM880, Carl Zeiss, Oberkochen, Germany). The results are shown in Fig.

As shown in FIG. 2, it was confirmed that the protein expression level of AQP5 was increased when the extract was treated with Java turmeric extract. This means that the Java turmeric extract of the present invention has an effect of enhancing saliva secretion through increase of AQP5 protein expression.

Test Example  1-3. Intracellular Ca ^{2 +} Through measurement Java turbulence  The efficacy of the extract to enhance the secretion of saliva

Human salivary gland cells (HSG) were cultured in two 100 mm dishes using DMEM (Hyclone) medium containing 10% FBS (Hyclone). When the cell density reached 95% in a 100 mm dish, the cells were collected and placed in a cuvette. Ca ^{2 +} indicator was placed in (Ca ²⁺ indicator) of fura-2AM cuvette (cuvette) after the cells are filled into the 5 ㎕ seolpin pyrazol zone (sulfinpyrazone, Thermo Fisher Scientific) to (Thermo Fisher Scientific) making sure that the color is changed. A cuvette was placed in a spectrofluorophotometer (RF-5301, Shimadzu, Kyoto, Japan), and a stirrer was operated to load the sample for 1 hour. After one hour, the cuvette was removed with Ca ^{2 +} cells in the (cuvette) in 1.5 ㎖ tube cleaning (washing) in DMEM (Hyclone) containing transferred to a (tube) in extracellular media (media). 900 Lock of Locke's solution and 100 ㎕ of cells suspended in DMEM (Hyclone) were placed in a cuvette and waited for 100 seconds. Then, 10 ㎍ of the extract from Java rhizome root of Example 1-1 / Ml. ≪ / RTI > Fura-2AM (Thermo Fisher Scientific) self-absorption wavelength of 380 nm with Ca ^{2 +} and bound fura-2AM (Thermo Fisher Scientific) and the absorbance of the two materials spectral fluorescence spectrophotometer in the 340 nm absorption wavelength of the (Spectrofluorophotometer, RF-5301 , was measured by Shimadzu), exhibited a rate of increase in Ca ^{2 +} cells as in Figure 3 F340nm / F380nm. After treatment compared to before treatment with a Java turmeric extract Ca ^{2 +} increase rate was calculated according to the following equation (1).

[Equation 1]

Intracellular Ca ^{2 +} increase (%) =

As shown in FIG. 3, the lowest value of the F340 / F380 ratio before treatment of the Java turmeric extract was 1.837, and the highest value of the F340 / F380 ratio after the treatment of the Java turmeric extract was 2.895. Because the 2.895 / 1.837 × 100 = 157.6% , the Ca ^{2 +} levels within cells by the Java turmeric extract was found to increase about 58%. This means that by the Java turmeric extract of the present invention to increase the Ca ^{2 +,} a major factor of saliva secretion mechanism has a salivation enhanced efficacy.

[ Test Example  2] Zanthoxyl  Verification of salivation enhancement efficacy

Test Example  2-1. RT- PCR  through Zanthoxyl  Verification of salivation enhancement efficacy

After the human salivary gland cells (HSG) were cultured in the same manner as in Test Example 1-1, the nansol sol obtained in Example 2 was dissolved at a concentration of 1 μM and 10 μM, and the cells were treated for 20 minutes. Then, RT-PCR was performed in the same manner as in Test Example 1-1. The results are shown in Fig.

As shown in Fig. 4, it was confirmed that the amount of mRNA expression of AQP5 was increased by the Nansorizu treatment. This means that the jazzori sol of the present invention promotes the expression of the AQP5 gene and thus has the saliva enhancing effect.

Test Example  2-2. AQP5  By comparing the expression levels of proteins Zanthoxyl  Verification of salivation enhancement efficacy

A pEGFP-C1 vector having an AQP5 coding sequence inserted therein was transfected into human salivary gland cells (HSG) in the same manner as in Test Example 1-2, and the zanthoxyl sol of Example 2 was added to a 10 μM concentration For 20 min. The GFP tagged AQP5 protein was photographed with a confocal microscope (LSM880, Carl Zeiss). The results are shown in Fig.

As shown in Fig. 5, it was confirmed that the protein expression amount of AQP5 was increased by the Nansorizu treatment. This means that the jazzori sol of the present invention has the effect of promoting salivary secretion by promoting AQP5 even at the protein level.

Test Example  2-3. Intracellular Ca ^{2 +} Through measurement Zanthoxyl  Verification of salivation enhancement efficacy

The intracellular Ca ²⁺ growth rate was calculated in the same manner as in Test Example 1-3 by treating the human salivary gland cells (HSG) with the jansori sol obtained in Example 2 at a concentration of 10 μM.

As a result, as shown in FIG. 6, the lowest value of the F340 / F380 ratio before the treatment with Janssol sol was 1.899, and the highest value of the ratio of F340 / F380 after the Jansori sol treatment was 2.925. 2.925 / 1.899 × 100 = 154.0%, it was found that the intracellular Ca ²⁺ level was increased by about 54% by the Nansorizol. This means that by the xanthorrhizol of the present invention to increase the Ca ^{2 +,} a major factor of saliva secretion mechanism has a salivation enhanced efficacy.

Hereinafter, examples of the preparation of medicines and foods containing the Java turmeric extract or Zanthoxylol as an active ingredient in Examples 1 and 2 according to the present invention will be described. The following Preparation Examples are intended to illustrate, but not to limit, the present invention. The pharmaceutical compositions and food compositions of Preparative Examples 1 and 2 were prepared according to a conventional method by using the Java corn steep liquor extract or Zanthoxylol sol, which is excellent in the saliva secretion enhancement or dry mouth symptom prevention, improvement or treatment effect of the present invention, according to the following composition components and composition ratios .

[ Manufacturing example  1] Medicines

Manufacturing example  1-1. Powder

50 mg of Javanese Turmeric extract or 2 g of crystalline cellulose were mixed in the above Examples 1 and 2 and filled in an airtight container according to a conventional acid preparation method to prepare a powder.

Manufacturing example  1-2. refine

The tablets were prepared by mixing 50 mg of Javanese Talc extract or 400 mg of crystalline cellulose and 5 mg of magnesium stearate in the above Examples 1 and 2 or tablets according to a conventional tablet preparation method.

Manufacturing example  1-3. Capsule

After mixing 30 mg of Javanese Turmeric extract or 100 mg of whey protein, 400 mg of crystalline cellulose and 6 mg of magnesium stearate in the above Examples 1 and 2, the mixture was filled in a gelatin capsule according to a conventional method for preparing a capsule, .

Manufacturing example  1-4. Injection

The active ingredient was dissolved in distilled water for injection and the pH was adjusted to about 7.5. Then, 100 mg of Nansorizol in Example 2, distilled water for injection, and pH adjusting agent were mixed and filled into a 2 ml volume ampoule And sterilized to prepare an injection.

[ Manufacturing example  2] Food

Manufacturing example  2-1. Manufacture of health food

The extracts of Examples 1 and 2 or Jansori sol 1000 mg, vitamin A acetate 70 ug, vitamin E 1.0 mg, vitamin B1 0.13 mg, vitamin B2 0.15 mg, vitamin B6 0.5 mg, vitamin B12 0.2 ug, vitamin C 10 10 mg of biotin, 1.7 mg of nicotinic acid amide, 50 mg of folic acid, 0.5 mg of calcium pantothenate, 1.75 mg of ferrous sulfate, 0.82 mg of zinc oxide, 25.3 mg of magnesium carbonate, 15 mg of potassium phosphate monobasic, 55 mg of calcium dihydrogenphosphate , Potassium citrate (90 mg), calcium carbonate (100 mg) and magnesium chloride (24.8 mg). The compounding ratio may be arbitrarily changed. The above ingredients are mixed according to a conventional method for preparing healthy foods, Granules can be prepared and used in the manufacture of a health food composition according to conventional methods.

Manufacturing example  2-2. Manufacture of health drinks

Purified water was added to 1000 mg of Javanese Turmeric extract or 1000 mg of Jansori sol, 100 g of citric acid, 100 g of oligosaccharide, 2 g of plum concentrate and 1 g of taurine according to the above Examples 1 and 2 to prepare 900 ml of the above- And the mixture is stirred and heated at 85 ° C for about 1 hour. The resulting solution is then filtered and sterilized in a sterilized 2 L container. The resulting solution can be stored in a refrigerator and then used in the manufacture of a health beverage composition.

Manufacturing example  2-3. Chewing gum

Chewing gum was prepared in a conventional manner by mixing 20% by weight of a gum base, 76.9% by weight of sugar, 1% by weight of a flavor and 2% by weight of water and 0.1% by weight of a Java turmeric extract or 0.1%

Manufacturing example  2-4. candy

A candy was prepared by blending 60% by weight of sugar, 39.8% by weight of starch syrup, 0.1% by weight of fragrance and 0.1% by weight of Javanese Turmeric extract or Jansori sol of Examples 1 and 2.

Manufacturing example  2-5. Biscuit

A mixture of 0.75% by weight of sodium chloride, 0.78% by weight of glucose, 11.78% by weight of palm shortening, 1.54% by weight of ammonium, 0.17% by weight of sodium bicarbonate and 0.16% by weight of sodium bisulfite, 25.59% by weight of Grade I, 22.22% 1.45 wt% of rice flour, 0.0001 wt% of vitamin B, 0.04 wt% of milk fractions, 20.6998 wt% of water, 1.16 wt% of whole milk powder, 0.29 wt% of replacement milk powder, 0.03 wt% of calcium phosphate, 0.29 wt% 7.27% by weight of milk and the Java turmeric extract or the nasal decaned sol of% by weight of the above Examples 1 and 2 were mixed to prepare biscuits by a conventional method.

Claims (19)

For enhancing saliva secretion comprising Curcuma xanthorrhiza extract or fraction thereof as an active ingredient, or for decreasing or inactivating salivary glands; Sjogren's syndrome; Chronic inflammatory disease; Radiation therapy or salivary gland injury caused thereby; Severe diarrhea; Systemic water loss; diabetes; Nutrient deficiency; Aging; Neurological diseases; Or for the prevention or amelioration of oral dryness or salivation by side effects of anticancer, antidiabetic, antidepressant or antiallergic drugs; Food composition. The method according to claim 1,
Wherein the extract is an extract of at least one solvent selected from the group consisting of water, an organic solvent having 1 to 6 carbon atoms, a subcritical fluid, and a supercritical fluid. delete 3. The method according to claim 1 or 2,
Wherein the extract or fraction thereof comprises a xanthorrhizol compound or a salt thereof. Functional decline or atrophy of salivary glands containing Curcuma xanthorrhiza extract or fractions thereof as an active ingredient; Sjogren's syndrome; Chronic inflammatory disease; Radiation therapy or salivary gland injury caused thereby; Severe diarrhea; Systemic water loss; diabetes; Nutrient deficiency; Aging; Neurological diseases; Or a pharmaceutical composition for the prevention or treatment of dry mouth or salivary gland dysfunction due to side effects of anticancer, antidiabetic, antidepressant or antiallergic drugs. 6. The method of claim 5,
Wherein the extract is an extract of at least one solvent selected from the group consisting of water, an organic solvent having 1 to 6 carbon atoms, a subcritical fluid, and a supercritical fluid. 6. The method of claim 5,
Wherein said fraction is a fraction by a mixed solvent comprising hexane and ethyl acetate for Java turmeric extract. delete 8. The method according to any one of claims 5 to 7,
Wherein the extract or fraction thereof comprises a xanthorrhizol compound or a salt thereof. For enhancing saliva secretion comprising xanthorrhizol of formula (1) or a salt thereof as an active ingredient, or for depressing or shrinking the salivary gland; Sjogren's syndrome; Chronic inflammatory disease; Radiation therapy or salivary gland injury caused thereby; Severe diarrhea; Systemic water loss; diabetes; Nutrient deficiency; Aging; Neurological diseases; Or for the prevention or amelioration of oral dryness or salivation by side effects of anticancer, antidiabetic, antidepressant or antiallergic drugs; Food composition.
[Chemical Formula 1]

11. The method of claim 10,
The xanthorrhizol may be obtained from Curcuma < RTI ID = 0.0 > xanthorrhiza ). < / RTI > delete Functional decline or atrophy of salivary glands containing the active ingredient of xanthorrhizol of formula (I) or a salt thereof; Sjogren's syndrome; Chronic inflammatory disease; Radiation therapy or salivary gland injury caused thereby; Severe diarrhea; Systemic water loss; diabetes; Nutrient deficiency; Aging; Neurological diseases; Or a pharmaceutical composition for the prevention or treatment of dry mouth or salivary gland dysfunction due to side effects of anticancer, antidiabetic, antidepressant or antiallergic drugs.
[Chemical Formula 1]

14. The method of claim 13,
The xanthorrhizol may be obtained from Curcuma < RTI ID = 0.0 > xanthorrhiza ). < / RTI > delete For enhancing saliva secretion comprising Curcuma xanthorrhiza extract or fraction thereof as an active ingredient, or for decreasing or inactivating salivary glands; Sjogren's syndrome; Chronic inflammatory disease; Radiation therapy or salivary gland injury caused thereby; Severe diarrhea; Systemic water loss; diabetes; Nutrient deficiency; Aging; Neurological diseases; Or for the prevention or amelioration of oral dryness or salivation by side effects of anticancer, antidiabetic, antidepressant or antiallergic drugs; Quasi-drug composition. For enhancing saliva secretion comprising Curcuma xanthorrhiza extract or fraction thereof as an active ingredient, or for decreasing or inactivating salivary glands; Sjogren's syndrome; Chronic inflammatory disease; Radiation therapy or salivary gland injury caused thereby; Severe diarrhea; Systemic water loss; diabetes; Nutrient deficiency; Aging; Neurological diseases; Or for the prevention or amelioration of oral dryness or salivation by side effects of anticancer, antidiabetic, antidepressant or antiallergic drugs; Quasi-drugs. For the enhancement of salivary secretion comprising xanthorrhizol or a salt thereof as an active ingredient, or a hypofunction or atrophy of the salivary gland; Sjogren's syndrome; Chronic inflammatory disease; Radiation therapy or salivary gland injury caused thereby; Severe diarrhea; Systemic water loss; diabetes; Nutrient deficiency; Aging; Neurological diseases; Or for the prevention or amelioration of oral dryness or salivation by side effects of anticancer, antidiabetic, antidepressant or antiallergic drugs; Quasi-drug composition. For the enhancement of salivary secretion comprising xanthorrhizol or a salt thereof as an active ingredient, or a hypofunction or atrophy of the salivary gland; Sjogren's syndrome; Chronic inflammatory disease; Radiation therapy or salivary gland injury caused thereby; Severe diarrhea; Systemic water loss; diabetes; Nutrient deficiency; Aging; Neurological diseases; Or for the prevention or amelioration of oral dryness or salivation by side effects of anticancer, antidiabetic, antidepressant or antiallergic drugs; Quasi-drugs.

Images